{"id":"W2587799561","doi":"10.1093/annonc/mdw373.10","title":"IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Atezolizumab; Medicine; Metastatic Urothelial Carcinoma; Internal medicine; Clinical endpoint; Urology; Oncology; Gastroenterology; Clinical trial; Cancer; Urothelial carcinoma; Nivolumab; Bladder cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004885572,0.0008007574,0.002221313,0.0009261038,0.0001750525,0.001865623,0.001684413,0.0008813223,0.002038266],"category_scores_gemma":[0.006539717,0.0005410755,0.003677382,0.001881793,0.0002752828,0.00146742,0.001016154,0.001664488,0.0006266318],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001456872,"about_ca_system_score_gemma":0.001362548,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001918604,"about_ca_topic_score_gemma":0.006362889,"domain_scores_codex":[0.9981387,0.0006911441,0.0001997017,0.000388921,0.0003552675,0.0002262856],"domain_scores_gemma":[0.9966109,0.0009353078,0.001163391,0.0004417434,0.0004689157,0.0003797252],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1114265,0.0008741216,0.5080549,0.005565451,0.02733761,0.0004672056,0.0002551148,0.005761282,0.01118153,0.0009231119,0.04144757,0.2867058],"study_design_scores_gemma":[0.01691916,0.01359793,0.8544688,0.000947567,0.03194187,0.001334939,0.0002107003,0.004405667,0.005521059,0.001216587,0.06929529,0.000140454],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8561091,0.04335497,0.002074194,0.003206977,0.0004536047,0.00062973,0.0850466,0.0005014843,0.008623386],"genre_scores_gemma":[0.8866152,0.007949332,0.003092406,0.003166632,0.0003506834,0.0004229372,0.09529401,0.0002139424,0.002894952],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004885572,"threshold_uncertainty_score":0.02583766,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1186885192596476,"score_gpt":0.4243890684159451,"score_spread":0.3057005491562975,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}